Search Results | Blood | American Society of Hematology

1-20 of 253

2 3 4 5

Sort by

Sort Order Select

Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Blood (2019) 134 (Supplement_2): LBA-3.

DOI: https://doi.org/10.1182/blood-2019-132405

Published: 2019

Journal Articles

A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3

Kwanza Price, MPH, Zhun Cao, PhD, Craig Lipkin, Scott Robinson, Deborah Ann Profant, PhD

Blood (2019) 134 (Supplement_1): 2213.

DOI: https://doi.org/10.1182/blood-2019-127075

Published: 2019

Journal Articles

Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Multicenter Retrospective Analysis

Jakub Svoboda, MD, Hatcher J. Ballard, BS, Steven M. Bair, MD, Rahul Banerjee, MD, Charalambos Andreadis, MD, Tatyana A. Feldman, MD, Elizabeth L. McCarthy, MSN, RN, Niloufer Khan, MD, Alison J. Moskowitz, MD, Victor M. Orellana-Noia, MD, Craig A. Portell, MD, Sarah J. Nagle, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, Elise A. Chong, MD, Stephen J Schuster, MD

Blood (2019) 134 (Supplement_1): 2855.

DOI: https://doi.org/10.1182/blood-2019-123741

Published: 2019

Journal Articles

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Pau Montesinos, MD PhD, Maria Calbacho, MD, Jordi Sierra Gil, MD PhD, Jaime Perez De Oteyza, MD PhD, Jacob M. Rowe, MB, BS, Ofir Wolach, MD, Yishai Ofran, MD, Yakir Moshe, MD, Jichao Sun, PhD, Jan Baughman, MPH, Eileen McNulty, MS, Ezio Bonvini, MD, Jon M. Wigginton, MD, Jan K Davidson-Moncada, MD PhD

Blood (2019) 134 (Supplement_1): 2662.

DOI: https://doi.org/10.1182/blood-2019-125966

Published: 2019

Journal Articles

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry

Blood (2019) 134 (Supplement_1): 2619.

DOI: https://doi.org/10.1182/blood-2019-129279

Published: 2019

Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Cynthia Z. Qi, MBA, Bhavik J. Pandya, PharmD, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 3859.

DOI: https://doi.org/10.1182/blood-2019-123819

Published: 2019

Journal Articles

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Colleen Annesley, MD, Corinne Summers, MD, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie Rivers, MD, Adam J. Lamble, MD, Ashley Wilson, PhD, Qian Vicky Wu, PhD, Adam Brand, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD, Rebecca Gardner, MD

Blood (2019) 134 (Supplement_1): 3869.

DOI: https://doi.org/10.1182/blood-2019-131447

Published: 2019

Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Bhavik J. Pandya, PharmD, Cynthia Z. Qi, MBA, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 5085.

DOI: https://doi.org/10.1182/blood-2019-123811

Published: 2019

Journal Articles

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Jorge E. Cortes, MD, Eunice S. Wang, MD, Justin M. Watts, MD, Sangmin Lee, MD, Maria R. Baer, MD, Kim-Hien Dao, DO, PhD, Shira Dinner, MD, Jay Yang, MD, William B. Donnellan, MD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Christian Recher, MD PhD, Patrick Kelly, MD, Jennifer Sweeney, Julie Brevard, Patrick Henrick, Sanjeev Forsyth, Sylvie Guichard, Hesham Mohamed, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS

Blood (2019) 134 (Supplement_1): 674.

DOI: https://doi.org/10.1182/blood-2019-124360

Published: 2019

Journal Articles

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Courtney D. DiNardo, MD MSc, Andre C. Schuh, MD, Eytan M. Stein, MD, Pau Montesinos Fernandez, MD PhD, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Stephane De Botton, Amer M. Zeidan, MBBS, MHS, Amir T. Fathi, MD, Lynn Quek, MD PhD, Hagop M. Kantarjian, MD, Mark G. Frattini, MD, Frederik Lersch, RN, Jing Gong, PhD, Aleksandra Franovic, PhD, Kyle MacBeth, PhD, Paresh Vyas, MD PhD, Hartmut Döhner, MD

Blood (2019) 134 (Supplement_1): 643.

DOI: https://doi.org/10.1182/blood-2019-130362

Published: 2019

Journal Articles

BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib

Blood (2019) 134 (Supplement_1): 170.

DOI: https://doi.org/10.1182/blood-2019-125488

Published: 2019

Journal Articles

Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax

Piers Blombery, MBBS, Ella Thompson, PhD BSc, Tamia Nguyen, Xiangting Chen, PhD, Michelle McBean, Richard W Birkinshaw, PhD, Peter E Czabotar, PhD, Rachel Thijssen, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, John F. Seymour, MBBS, PhD FRACP, David Alan Westerman, MBBS, FRCPA, FRACP, David C.S. Huang, MBBS MRCP PhD, Andrew W. Roberts, MBBS, PhD

Blood (2019) 134 (Supplement_1): 171.

DOI: https://doi.org/10.1182/blood-2019-125457

Published: 2019

Journal Articles

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 231.

DOI: https://doi.org/10.1182/blood-2019-123920

Published: 2019

Journal Articles

Major Adverse Cardiac, Arterial Occlusive, and Venous Occlusive Events Among Chronic Myeloid Leukemia Patients Prescribed Ponatinib Vs Bosutinib

Moshe Yair Levy, MD, Lin Xie, MA, MS, Yuexi Wang, Frank Neumann, MD PhD, Shouryadeep Srivastava, MBBS, PhD, Daniel Naranjo, Jing Xu, Qisu Zhang, MPH, Mehul Dalal, PhD

Blood (2019) 134 (Supplement_1): 4751.

DOI: https://doi.org/10.1182/blood-2019-129053

Published: 2019

Journal Articles

Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a US Hospital's Perspective

Hongbo Yang, Yanni Hao, PhD, Cynthia Z. Qi, MBA, Xinglei Chai, PhD, Eric Q Wu

Blood (2019) 134 (Supplement_1): 4723.

DOI: https://doi.org/10.1182/blood-2019-129215

Published: 2019

Journal Articles

US Cost Burden of Relapsed Refractory Multiple Myeloma during Third and Later Lines of Treatment

Gene Felber, PhD, Chi-Chang Chen, Jenny Willson, Chris Bell, Edgar Simard, Sasikiran Nunna, Chandrabhan Dharmani, Heide Stirnadel-Farrant, Feng Wang, Amanda Bruno

Blood (2019) 134 (Supplement_1): 4725.

DOI: https://doi.org/10.1182/blood-2019-130791

Published: 2019

Journal Articles

A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation

Clara Chen, PhD BS, MS, Philippe Armand, MD PhD, Basia Rogula, Karissa Johnston, Derek Peterson, Joseph M Connors, MD, Greta Lozano-Ortega, MSc

Blood (2019) 134 (Supplement_1): 4761.

DOI: https://doi.org/10.1182/blood-2019-122302

Published: 2019

Journal Articles

Incidence and Cost of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with and without Multi-Organ Dysfunction: Analysis of the Premier Healthcare Database

Christopher C. Dvorak, MD, Zhun Cao, PhD, Kwanza Price, MPH, JeanPierre Coaquira, Craig Lipkin, Scott Robinson, Partow Kebriaei, MD

Blood (2019) 134 (Supplement_1): 4706.

DOI: https://doi.org/10.1182/blood-2019-123499

Published: 2019

Journal Articles

Next Generation Sequence Minimal Residual Disease (NGS-MRD) Predicts Outstanding Event Free Survival (EFS) Regardless of Hematopoietic Cell Transplantation (HCT) Preparative Approach or Graft Alpha/Beta Depletion in Children with Acute Lymphoblastic Leukemia (ALL)

Hisham Abdel-Azim, Christopher C. Dvorak, MD, Nancy Bunin, MD, Mark C. Walters, MD, Julie-An Talano, MD, Eric Jon Anderson, MD, Jemily Malvar, MS, May Al Jassani, Sonali Chaudhury, MBBS,MD, Mitchell S Cairo, MD, Carrie Kitko, MD, Allison P. Jacob, Dimitri S. Monos, PhD, Leung Wing, MD PhD, Michael A. Pulsipher, MD

Blood (2019) 134 (Supplement_1): 4624.

DOI: https://doi.org/10.1182/blood-2019-131706

Published: 2019

Journal Articles

Economic Burden of Neurologic Toxicities Associated with Treating Relapsed Refractory Diffuse Large B-Cell Lymphoma in the United States

Michael S Broder, MD MSHS, Qiufei Ma, PhD, Tingjian Yan, PhD, Eunice Chang, PhD, Lamis K. Eldjerou, MD, Yanni Hao, PhD, David Kuzan, MD, Jie Zhang, PhD

Blood (2019) 134 (Supplement_1): 4719.

DOI: https://doi.org/10.1182/blood-2019-122587

Published: 2019

2 3 4 5

NARROW

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3

Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Multicenter Retrospective Analysis

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib

Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Major Adverse Cardiac, Arterial Occlusive, and Venous Occlusive Events Among Chronic Myeloid Leukemia Patients Prescribed Ponatinib Vs Bosutinib

Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a US Hospital's Perspective

US Cost Burden of Relapsed Refractory Multiple Myeloma during Third and Later Lines of Treatment

A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation

Incidence and Cost of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with and without Multi-Organ Dysfunction: Analysis of the Premier Healthcare Database

Next Generation Sequence Minimal Residual Disease (NGS-MRD) Predicts Outstanding Event Free Survival (EFS) Regardless of Hematopoietic Cell Transplantation (HCT) Preparative Approach or Graft Alpha/Beta Depletion in Children with Acute Lymphoblastic Leukemia (ALL)

Economic Burden of Neurologic Toxicities Associated with Treating Relapsed Refractory Diffuse Large B-Cell Lymphoma in the United States

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only